Non-squamous NSCLC
Clinical trialCheckMate 05715 KEYNOTE-01011 OAK16
DrugNivolumabDocetaxelPembolizumab*
2–10 mg/kg
DocetaxelAtezolizumabDocetaxel
No. of patients287268444240313315
m OS12.29.5NANA15.611.2
HR0.75 (0.63–0.91)0.63 (0.50–0.79)0.73 (0.60–0.89)
1-year OS (%)513943/52§35§55§41§
2-year OS (%)291330.1a/37.5b §14.531§21§
3-year OS (%)189
  • m OS, median overall survival.